Healios KK (JP:4593) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Healios KK, in collaboration with Sumitomo Pharma, has initiated a phase 1/2 clinical study for treating retinal pigment epithelium (RPE) tears using allogeneic iPS cell-derived RPE cells, with the first patient enrolled at Kyushu University Hospital. The study aims to commercialize the treatment and establish its efficacy and safety to benefit patients swiftly. As of now, the development has no confirmed impact on Healios KK’s financial performance for the fiscal year.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.